Abstract: Neurons in the CNS establish exceedingly complex and precise networks organised via specific synaptic connections that ultimately determine the cellular basis of cognitive processes and behaviour. This fragile and intricate circuitry presents a challenging barrier for fundamental neurobiology studies or clinical gene therapy where long-term genetic modification is wanted. Small volumes, low toxicity, minimal immune reaction, slow delivery times, and preferential targeting of specific cell types in selected subregions are often sine qua non for vector-mediated gene transfer. This review addresses the state-of-the-art of gene transfer to the CNS, in particular the use of adenovirus, herpes simplex virus, adeno-associated virus, simian virus 40 (SV40), lentivirus and alphavirus vectors. The advantages and drawbacks of these molecular tools with respect to their tropism; ability to traffic via axoplasmic retrograde transport; duration of transgene expression; innate, adaptive and memory immunity; and toxicity are discussed.
I) INTRODUCTION
There are more genes expressed in the central nervous system (CNS) than in any other mammalian tissue, making the brain the most functionally and genetically complicated organ [1] . Anatomically and functionally distinct clusters of neuron cell bodies, or nuclei, are dispersed throughout the brain. Concomitantly, neurons develop exceedingly complex and precise networks between these nuclei and the patterns determined by specific synaptic connections control the cellular basis of cognitive processes and behaviour. This creates a formidable temporal and spatial complexity that confronts functional genomic as well as therapeutic questions, which often require flexible and efficient gene transfer platforms for in vitro and in vivo studies. In the CNS the proportion of glia, relative to neurons, increases with the evolution of the species until they represent 90% in man. In addition, the CNS has a unique immunological setting due to the blood brain barrier, a specialized non-fenestrated tightly joined endothelial cell layer that impedes the transport of certain substances between the cerebral capillaries and the CNS. This barrier is thought to protect (among other roles) the fragile CNS from aggressive and potentially lethal inflammation induced by an immune reaction.
In many laboratories efficient genetic modification of neurons may be the Holy Grail of CNS-targeted gene transfer. If one wanted to modify these terminally differentiated cells, what would one look for in a vector? Thanks to hundreds of millions of years of evolution and the last ~35 years of molecular biology, viruses have been subverted from their presumed fiendish role to that of molecular dissecting tools. The misunderstood viruses must be happier in their nascent role as potential saviours. Too often one hears that viruses are clever, calculating and mischievous entities constantly evolving to get an upper hand on a host. One could however, imagine that these pieces of nucleic acid wrapped by protein were originally a benign part of a cell, which probably discarded them like used trash. Like a paparazzo plague, a meddlesome cell picked up the harmless trash, modified it and then discarded again. Just like the 21 st century virus, their primordial cousins were probably lethargic and happy to be recycled into something innocuous and useful. However, cells keep pulling them inside, modifying their genomes, and then spitting them out again. Viruses must be begging to be left alone-they do not want to evolve. Leave the virus alone and she does nothing: mix her with a bad cellular crowd and things go wrong (the selfish cell is the culprit). On the other hand, mix her with a molecular virologist and the future starts to look brighter. Viral vector-mediated gene transfer to the CNS has matured significantly in the last 15 years. Although efficient and clinically relevant gene transfer may still have a way to go, fundamental and preclinical gene transfer studies are quickly unravelling the CNS labyrinth.
Several areas of interest for genetic modification of the CNS tissue might include: i)
In vitro analyses of gene function in a subset of cells: i.e. oligodendrocytes, macro-and microglia, and the various subtypes of neuron (dopaminergic, cholinergic, adrenergic, etc).
ii) Genetically modifying existing animal models to better understand the pathophysiological condition involved in a neurodegenerative disease while using environmental factors and genetic predisposition to mimic the clinical phenotype (for recent review [2] ).
iii) High-throughput assays of uncharacterised gene products in various brain regions (e.g. in organotypic cultures) to understand their spatial and temporal role.
iv) Creating complex animal models via gene transfer where the expression of several genes could be combined and regulated pre-and post-transcriptionally, or post-translationally (e.g. via Cre recombinase fused to mutated ligand binding domain of the estrogen receptor [3, 4] ).
v) Understanding the immune privilege status of the CNS.
vi) Derive clinically relevant vector for the treatment of neurodegenerative diseases.
These scenarios are certainly not mutually exclusive. Fortunately for studies requiring gene transfer, the intrinsic characteristics of the mammalian CNS as an immune privileged organ [5] may preclude one possible and unavoidable paradox of gene therapy: how to generate longterm stable expression of a protein that the body has never seen before-and therefore treating it as nonself and immunogenic.
The choice of a vector for in vitro, ex vivo, or in vivo studies depends on many different parameters including the duration of expression needed, the cell type targeted, the ease of vector construction, cloning capacity, etc. What vector can transduce which cells, using which receptor are some of the fundamental questions that many are trying to solve. Naïvely, one may choose a vector derived from a virus that naturally induces clinical symptoms in a target organ. Herpes simplex virus type 1 (HSV-1) was an obvious choice for CNS gene transfer studies that targeted neurons in the 1980's [6] . Paradoxically, this may be one of the few vectors that has a tropism mimicking the natural reservoir of the virus. Adeno-associated viruses (AAV) (at least the serotypes currently known) are found primarily in the liver, but also in the brain of primates [7] . Lentiviruses, e.g. human immunodeficiency virus type 1 (HIV-1) can be found in the CNS [8] but poorly infect neurons in vitro. If one considers adenovirus type 2 (Ad2) gene transfer, originally considered as an ideal tool for gene transfer to the respiratory tract (its natural site of clinical symptoms in man), preclinical and clinical assays have been disappointing in airway epithelia because the coxsackievirus and adenovirus receptor (CAR), a highly conserved cell adhesion molecule [9, 10] , is sequestered in tight gaps junction on the basolateral surface [11] . Not surprisingly, we have moved a long way from the virussymptoms -ipso facto -vector-tropism concept as the field of gene transfer has matured. Viruses can generate tissuespecific clinical symptoms that poorly correlate with its vector tropism, which obviously is often due to the mode of instillation. There is also a significant difference in the physiological response between a naturally occurring viral infection and the massive dose delivered via a specific route (e.g. stereotactic injections) during gene transfer experiments [12] , and classical immunological studies of virus-host response are only partially relevant in this context. Direct injection into the immune privileged CNS also opens a unique niche in immunology.
In the context of this review intracerebral injections are primarily addressed. Small injected volumes, low cellular toxicity, minimal immune reaction, slow delivery times, and preferentially targeting specific cell types in defined subregions are often sine qua non for vector-mediated gene transfer. Delivery via the systemic circulation leads to poor gene transfer in the CNS in mature animals due to the blood brain barrier, and therefore vector instillation has been more efficient via direct injections. However, there have been several encouraging approaches to transiently open the blood brain barrier via osmotic disruption [13] , but they will not be discussed here. In the rapidly evolving field of viral vector mediated gene transfer a collection of some interesting vectors is presented. The review is primarily focused towards those who are looking for the most appropriate gene transfer platform for the CNS, and an elementary knowledge of the brain anatomy is assumed.
II) VECTORS
Throughout the early 1990's, an ambiance one might call "the vector war" was warming the gene therapy conference circuit. It often appeared that by the end of the introduction of many exposes, only the vector used by the orator's group should be considered as potential tool for gene transfer (in most tissues). Throughout that combative period, there were those reminding us that no single vector would be appropriate for all diseases, or all tissues, and that the advantages of different viral and synthetic vectors should be combined into hybrid vectors. Currently, each viral vector has its specific profile of advantages and drawbacks for modification of cells in the CNS, such as tropism, cloning capacity, memory or adaptive immunity, toxicity, specificity, safety, titre, or efficacy. It is highly likely that the list of vectors described here will expand, mature and become more powerful in the near future. Hybrid vectors, in particular those that combine viruses from different families have not been extensively studied in the CNS, probably because of the technical expertise needed for in vivo gene transfer. The vectors discussed below are divided artificially into DNA virusesadenoviruses (human and canine), adeno-associated viruses, herpes simplex type 1 and simian virus 40; and RNA viruses -alphaviruses, and lentiviruses (retroviruses) (Fig. 1) .
III) DNA VIRUS VECTORS

IIIa) Adenoviridae
Ad is a family of ~90 nm icosahedral (Fig. 1a) , nonenveloped, double-stranded DNA viruses of 25 to 45 kb. Human Ads normally cause self-limiting infection in healthy children and adolescents, although they can be lethal in infants and severely immunocompromised patients [14, 15] . Human Ad tropism varies with the species (A through F) serotype (1 through 52) and include the respiratory, urinary and gastrointestinal tracts, ocular, and cardiac tissue [15] . Ads are found throughout the planet in mammals, amphibians, reptiles, and birds and are rarely considered as a naturally "neurotropic" virus. However, for many years some human and nonhuman serotypes [16] have been associated with encephalitis, suggesting that some Ad serotypes may naturally infect some cell types in the CNS. Of the current 52 human serotypes [15, 17] , Ad3, 4, 7, 11, 17, 31 and 49 may be possible CNS pathogens. The presence of Ad (by electron microscopy, isolation or amplification) or anti-Ad antibodies in the cerebral spinal fluid has normally been the criteria used to demonstrate the association with encephalitis. However, this correlation does not prove a causative effect. Unless otherwise noted, Ad2 and 5 (which are essentially equivalent) will be discussed because most of the data on Ad biology has been generated using species C. Nonetheless, within the last 5 years several other Ad serotypes have been converted in vector platforms. Unfortunately, their use in gene transfer to the CNS has been limited to a few (e.g. Ad17 [18] ).
The Ad capsid is composed of three major oligomeric proteins. The trimeric hexons form the 20 faces of the icosahedral capsid, which is sealed at each of the 12 vertices by a complex of the pentameric penton base and an outward extending homotrimeric fibre. Ads replicate extra-chromosomally and have no natural tendency to integrate into the cellular genome because they normally lyse the cell during a productive infection of permissive host cells. The extrachromosomal status also includes Ad vectors (which makes them less attractive for use in dividing cells). Nonetheless, the linear Ad genome has an insertion rate slightly above plasmid DNA, and several orders of magnitude below retrovirus vectors [19, 20] .
The advent of Ad vectors began in the mid 80's and the vectors were derived predominantly from serotypes 2 & 5 and are the prototypes. "First-generation" vectors were often deleted in the early 1 (E1) and 3 (E3) regions (∆E1/E3 vectors) and have a maximal cloning capacity of ~8 kb (~110% of the wild type genome) [21] . The size limit is certainly due to the inflexibility of the Ad capsid, which limits the quantity of DNA that can be packaged. Relative to most of the other vectors discussed here, Ads have been subjected to a large variety of modification of their external capsid proteins (fibre, penton base, pIX -a minor structural protein, and hexon). The penton is a complex of primarily two oligomeric proteins, a penton base and the fibre, which are involved in the cell attachment, internalization, and release of virus into the cytoplasm [22] . Unlike a few of us (see below), most laboratories believe that α v integrins play a significant role as auxiliary receptors and aid in Ad internalisation [23, 24] . The fibre knob is generally the key player in Ad vector tropism. However, there are many variables affecting tropism such as the interaction with secondary receptors [23] , the rigidity and number of repeats in the Ad fibre shaft [25] *, the presence of integrin-interacting motifs in the external regions of the capsid [26, 27] , and the overall external charge of the capsid [28, 29] . The fibre knob has been dissected, mutated, and co-crystallized with CAR to identify the contact points [30, 31] . A small subset of the numerous modifications used to modify the tropism includes variation of the fibre shaft length; switching of fibre knob from other nonhuman species [32] ; and replacement, substitution, addition of receptor binding motifs in the knob, as well as penton and hexon. Unfortunately, only a handful of the modified Ad vectors has been tested in the CNS to date.
Ads have a broad tropism in the CNS tissue, which some consider as a liability or an advantage depending on ones objectives. In vitro, Ad vectors efficiently transduce ependymal and parenchymal cells of the CNS (Fig. 2a-c) . In vivo, Ad vectors preferentially transduce astrocytes (~60%) when injected into the striatum or hippocampus of rodents or primates [33, 34] . They also transduce neurons (25 to 30%), oligodendrocytes (~5 to 10%), and microglia (~1 to 5%). By targeting other coordinates and structures in the CNS for vector delivery the tropism and cell type ratios can vary. Greater than 10 years ago Le Gal La Salle et al. demonstrated retrograde transport to the substantia nigra pars compacta (SNpc) following injection into the rat striatum [34] . However, in contrast to some of the other viral vectors discussed below, most laboratories routinely find a modest levels of axoplasmic retrograde transport when Ads are injected into the CNS [34] . Fig. (1) . Electron micrographs (EM) or CryoEM of the viruses discussed: a) EM canine adenovirus type 2; ~90 nm diameter (Image generated by Dr. Olivier Billet and Dr. Guy Schoen EMBL Grenoble, France); b) CryoEM of ~22 nm diameter AAV type 5 at 16 Å resolution [291] . This is a view down an icosahedral 2-fold axis (Image provided by Dr. Mavis A. Mckenna, Center for Structural Biology, University of Florida, Gainesville, Florida, USA); c) herpes simplex type 1; ~100 nm. Three-dimensional CryoEM structure of the capsid coloured according to the particle radius. The capsid shell (yellow) is decorated by 12 pentons and 150 hexons (light blue) connected by 320 triplexes (green). (Image provided by Dr. Z. Hong Zhou of the University of Texas Medical School at Houston, USA); d) EM of simian virus 40 which is ~45 nm in diameter; e) EM human immunodeficiency virus. One can see a virion budding, some immature (with the thick capsid) and some mature virions (Image generated by Bernard Gay, UMR5121, CNRS-UMI, Montpellier, France); and f) EM of Togavirus.
Advocates of Ad-mediated gene transfer for long-term therapy have a difficult time shedding the unflattering reputation of propping up an immunogenic vector. ∆E1 Ad vectors are notorious for their ability to induce CD8 + cytotoxic T cell (CTL)-mediated destruction of transduced cells in most tissues, and in most immunocompetent animals. The induced immunogenicity is due, in part, to the low level expression of the >80% of the viral genes that remained in the vectors [35] . The understanding of the short duration of Ad-mediated transgene expression was complicated by i) the different protein expressed, ii) the protein's subcellular localization (nucleus, cytoplasm, cell surface or secreted), iii) the tissues transduced, iv) the strain and haplotype of rodent used in the studies; v) the variability of the vector preparation; and vi) the inconsistencies in reporting the dose of vector delivered [12, 36] .
Ad vectors have a relatively notorious history, exacerbated by the death of an adolescent during a 1999 Phase I trial [37] . This trial was for a monogenic, metabolic disorder of the liver (ornithine transacarbamylase-deficiency) using 3.6 x 10 13 particles of a ∆E1/E4 vector injected in the portal vein. Mild symptoms were initially reported, then ~24 hr postinjection the patient's status deteriorated showing an elevation in cytokine levels, and subsequently he was mechanically ventilated. A systemic inflammatory response syndrome, lack of tissue oxygenation due to adult respiratory distress syndrome, and subsequent multi-organ failure probably followed. The reasons for this death are multifactorial and may never be completely understood because a number of variables obscure the interpretation of the patient's clinical course. Although the injection of the human Ad vector played the significant role in the death, other factors influencing the outcome must also be considered (e.g. the level of pre-existing humoral and cellular immunity). Nonetheless, this demonstrated the significant variation among patients likely to be found. This type of use for Ad vectors in the clinic however is in the minority. Most trials using Ad vectors are for cancer therapy [38] , including brain tumours.
The long-term consequence of Ad transfer in the rodent brain is partially characterized and reviewed elsewhere [12] . Due to its immune privileged status, the CNS is a partial exception to the general rule of short-term expression of ∆E1 Ad vectors in immunocompetent animals. In spite of a dosedependent acute inflammation, modest doses (e.g. 10 8 infectious units) can lead to relatively long transgene expression (18 months) [39, 40] . However, transgene expression levels are generally stable for <6 months at ~10 8 infectious units/injection. At high multiplicity of infections (>5 x 10 8 infectious units/injection), Ad vectors can be cytotoxic to neurons and glia in vivo [41] [42] [43] , and induce a T cellindependent and a T cell-mediated response in naïve animals [44, 45] . Ad-mediated gene transfer to rodent brain induced a humoral [43] and cellular immune response [41] , and the latter was augmented when a vector was then administered systemically [45, 46] . Several laboratories showed that ∆E1 Ad vectors also induce demyelination in the rodent brain [41] [42] [43] 46] , which is increased following peripheral readministration of the vector. Lowenstein and colleagues showed that following Ad-mediated gene transfer in the brain, and then re-challenged subcutaneously, an increased CD4 + and CD8 + T cell infiltration developed in the CNS [45, 47] . Glia activation (e.g. upregulation of glial fibrillary acidic protein in astrocytes), which is part of the innate immune response [48] , is probably due to the transduction of macroglia by Ad vectors.
The characterisation of the Ad-induced signalling cascade, which also causes a focal reorganisation of actin filaments [49] via a stimulation of a host of tyrosine kinases [50] and induces internalisation has been performed primarily in epithelial cells, but is likely to be similar in glia. The innate response leads to cytokine and chemokine expression and secretion, which attract cellular infiltration (naïve and memory T and B cells, macrophage, and natural killer cells). The memory cellular (T M ) and humoral immunity may therefore heighten the Ad-induced immune response and increase neurodegeneration [51] . Polyclonal activated CD4
+ and CD8 + T cell infiltration can induce neuronal death by cell contact via FasL, LFA-1 and CD40 pathways [52] . This mechanism is also major histocompatibility complex (MHC) class I-independent. Phase I trial of adenosine deaminase-deficiency suggests that CD4 + T M survive for up to 10 years [53] . In the case of the Ad-specific CD4 + T M response, it cross-reacts with other serotypes [51] . Virus-specific memory CD4 + and CD8 + T cells evolve throughout our life and vary among the different pathogens. This clonal variation of T M is driven by a complicated maturation based partially by the frequency of re-exposure [54] . Because many Ad serotypes are endemic, repeat reexposure is probably common.
Since late 1996, the state-of-the-art Ad vector is a helperdependent, high-capacity, or more colourfully called "gutless" vectors [55, 56] . Gutless vectors are generated by the helper-dependent mobilization (replication and packaging) of a linear DNA molecule containing the expression cassette, flanked by the inverted terminal repeats and cis-acting packaging domain (Ψ) (<500 bp of the Ad genome). Briefly, replicating and packaging the gutless construct in a cell that is co-infected with an "unpackagable" helper vector, which supply in trans all the necessary factors, produces a gutless vector. In the most common system a helper vector is rendered unpackagable by flanking the Ψ by loxP sites and propagating in Cre recombinase expressing cells [57, 58] . Cre expression excises the Ψ of the helper vector and the gutless vector is preferentially packaged and then purified. Comparable systems using the FLPe recombinase have also been described [59] . Gutless vectors are deleted in the entire Ad coding region, non-toxic, can be concentrated to ~10 12 infectious particles/ml and >10 13 physical particles/ml [60] , and have a cloning capacity of 25 to 38 kb [21, 55] . An early drawback was that gutless vector production could be technically difficult and it was mastered by a handful of laboratories. Recently Palmer and Ng modified, improved, and simplified the conditions for gutless vector preparation [60] .
In primary cerebellar granular cell (CGC) cultures, gutless Ad vectors were notably less toxic than ∆E1 vectors. Following incubation with a ∆E1 vector, CGC undergo a global shut down in host protein synthesis, impaired physiological functions, and increased apoptosis 3 to 5 days posttransduction [61] . In contrast, incubation with equal quantities of gutless vectors (enough to transduce 85% of the cells) caused a modest effect on the cell physiology after 7 days posttransduction. Nonetheless, at higher doses of gutless vectors though, an adverse effect was found 7 days posttransduction, suggesting that de novo expression of virus-encoded genes in combination with the internalised capsid proteins cause the early cytopathic effect, and the capsid proteins contribute to a delayed cellular response.
In naïve immunocompetent laboratory animals, much of the adaptive immune response has been significantly reduced when using gutless vectors because the CD8 + CTL destruction of transduced cells has been essentially eliminated [62] . Doses of 10 9 infectious units can be injected in the CNS without breaching the toxicity barrier and inducing the immune-mediated destruction of the transduced cells. In most animals, transgene levels remain stable 1 to 2 years posttransduction with a modest reduction of <50% [21, 63] .
In contrast to preclinical animal studies, clinical systemic Ad-mediated gene transfer has been disappointing. A difference in pre-existing humoral immunity directed against the vector capsid certainly helps explain, in addition to other factors, the variability between and within Phase I/II trials [64, 65] . In almost every population tested, >90% of the cohort harboured anti-Ad antibodies, and >60% had relatively high levels of neutralising antibodies [66] . Furthermore, when repeat vector administrations were attempted during phase I trials, transgene activity was rarely detected due to the boost in neutralising antibody production [67, 68] . In addition to the humoral response, 29/30 individuals from a random cohort had a long-lived proliferative CD4 + T M response against the capsid proteins of multiple serotypes [51, 69] . A proliferative cellular response also cross-reacted against rare serotypes (e.g. Ad35) in which patients had no serological evidence of prior infection. These data suggest the presence of common capsid antigenic epitopes (probably due to the hexon) [70] , and that human serotype-switching [71] may have limited advantages.
IIIb) Nonhuman Adenoviridae
We and others [72, 73] started developing nonhuman Ad vectors greater than 10 yrs ago believing that vectors derived from ubiquitous viruses that naturally infect and replicate in humans (or possibly primates [74] ) may be poor candidates for clinical applications. Structural comparison of the capsid proteins suggests that Ads are ancient and have a common origin with enterobacterium phages from the family Tectiviridae [75] . This also implies that Ads have undergone a long coevolution with vertebrate hosts [76] . Although >30% of all known Ads are thought to be human species (some so-called human Ads may have crossed the species barrier and be from nonhuman primates), this should not be interpreted as a pretext to label it a partisan virus. The more one looks in a specific host the more one finds, and for obvious reasons the scientific community has concentrated on the clinically relevant species. Ads have been isolated or detected (often by electron microscopy) from many other mammals, reptiles, amphibians, birds, and marsupials [15] . To the best of my knowledge, only one nonhuman Ad has been tested in the CNS and the results are worth noting.
CAV-2 Vectors
Canine Ad serotype 2 (CAV-2) normally causes a mild respiratory tract infection (commonly known as kennel cough) in young dogs [77] , and is reminiscent of the symptoms caused by Ad2/5 in humans. {Interestingly, the first reported isolation of CAV-2 might have been from a fox brain in 1925, although shifting nomenclature has clouded the trail. Similarly, the first isolation of a caprine Ad was isolated from the brain of a 3-year old goat [16] .} We developed vectors derived from the Toronto strain of CAV-2 [78] with the initial raison d'être based on the simple observations that:
Ad vectors performed well in vivo in immunologically naïve nonhuman models. ii) Ad vectors performed poorly in animals previously exposed to the human Ad vector/virus.
iii) The majority of potential patients have a significant memory humoral and cellular immunity to many Ad serotypes. iv) Wild type Ad infections are relatively species-specific, and share limited cross-reacting antigenic epitopes.
v) Nonhuman species may have different tropism to the classic (species C) Ad vectors.
We predicted that nonhuman Ad vectors could avoid some of the clinical disadvantages of their human cousins, while keeping many of the advantages. ∆E1 CAV-2 vectors can be grown to high titres (>10 13 physical particles/ml) and are replication-defective in canine cells, as well as in all human cells tested. ∆E1 CAV-2 vectors gave encouraging results i) in vitro for their efficacy to transduce human cell compared to Ad5 [78] ; ii) for the lack of replicationcompetent CAV-2 contaminating the stocks [63, 79] , and iii) for the particle to infectious unit ratio (<3:1) (the best reported for a viral vector) [73] . We found that sera from 49/50 individuals from a random cohort did not contain significant levels of CAV-2 neutralizing antibodies [78] . Preliminary results also suggest that there is a significantly lower proliferative T M response against the CAV-2 capsid (versus Ad5) in the majority of humans (M Perreau & EJ Kremer unpublished data).
In primary rodent spinal cord, cortical, hippocampal, and CGC neuron cultures CAV-2 vectors efficiently transduced the majority of neurons in the cultures at modest particle/cell ratios while poorly infecting glia and oligodendrocytes ( [63] and unpublished data). An example of the complementary transduction efficiency of Ad and CAV-2 vectors was seen when each vector was incubated with primary mouse CGC, striatal, hippocampal, cerebellar, and collicular neurons (Fig.  2) .
In vivo transduction patterns of CAV-2 vectors (Fig. 3 ) also lead to preferential transduction of neurons [80] . Notably absent from the injection site in the rat striatum was the cluster of transduced glia found with Ad vectors [33, 34] . Following co-injection of Ad and CAV-2 vectors, a modest level of retrograde axonal transport of Ad vectors was observed into afferent structures (axonal projections into the striatum) [81] . Surprisingly, CAV-2 poorly infected glia, and was transported up to 10 3 -fold more readily than Ad to the ipsilateral and the contralateral neocortex, the SNpc, the centromedian nucleus and the basal nuclei of Meynert (BNM). Following injections in the mouse neonate gastrocnemius (hindleg muscle) the surprising level of axoplasmic retrograde was also seen. Although these latter CAV-2 vector injections lead to a poor transduction of skeletal muscle, the ipsilateral anterior horns of the sacral dorsolombar rachis contained clusters of transduced motoneurons. From these data, it was estimated that the axoplasmic retrograde transport of CAV-2 was ~50-fold greater than Ad. How CAV-2 is able to traffic "more efficiently" in the axoplasm is unknown, but being addressed.
Although pre-clinical animal testing is indispensable during the development of viral vectors, it may poorly reflect the result obtained in humans. Towards the goal of being clinically relevant, CAV-2 vector transduction was assayed in human cortical epileptogenic brain biopsies [80] and again preferentially (~90%) infected neurons. Why do CAV-2 vectors preferentially transduce neurons? In vitro CAV-2 bound CAR, a highly conserved cell adhesion molecule [82] , and used it to infect cells [28] . More relevant here, and unlike Ad5, CAV-2 attachment appeared to be independent of i) α M β 2 integrins [83] , ii) the α-2 domain of the MHC class I molecule [84] , and probably iii) α v β 1/3/5 and α 5 β 1 integrins [26] . In primary rat motoneuron cultures, anti-CAR antibodies co-localized with anti-MAP-2 antibodies: notably, CAR expression was found primarily, if not exclusively, on neurons (i.e. not on astrocytes or oligodendrocytes). The expression of CAR by neurons in the CNS, muscle and nasal cavity presumably enabled CAV-2 to preferentially transduce these cells [80] .
Although the biological effect of CAV-2 vector gene transfer has not been tested thoroughly, Morante-Oria et al. found that early-born mouse neurons in the medial ganglionic eminence could be i) transduced by ∆E1 CAV-2 vectors in organotypic slices, ii) migrate to the neocortex, iii) display a voltage-gated sodium current, iv) express functional alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, and v) show gamma-aminobutyric acid type A postsynaptic events that were modulated by presynaptic AMPA receptors [85] . These data suggest that ∆E1 CAV-2 vector internalisation did not significantly disrupt the normal physiology of differentiating mouse neural progenitor cells.
Like high doses of ∆E1 Ad vectors, CAV-2 transduced cells could be detected for several months in vivo, although with a decrease of ~75% from the peak at week 2. Based on these data, the decline in transgene expression was probably due to the low level of expression of cytotoxic viral proteins. Using a collection of new approaches we generated and tested the in vivo efficacy of gutless CAV-2 vectors in the rat CNS [63]**. Helper vectors were based on the mutations of the CAV-2 Ψ [79] and Cre recombinase expressing cells [57] , and stocks of ~2 x 10 10 infectious units/ml were generated. We estimate that gutless CAV-2 vector have a cloning capacity of at least 34 kb. The addition of a Ψ mutation in combination with the conditional removal via Cre/loxP acted in synergy to increase the purity and titre of gutless vectors. Gutless CAV-2 vectors were non-toxic, nonimmunogenic, and stable for >12 months in vivo in naïve animals. Fig. (3) shows transduction of the SNpc, BNM, and striatum from a single, or triple, injection of a gutless CAV-2 vector expressing GFP. Up to 50% of the GFP + cells at week 2 were still present at 52 weeks and multiple injections (3 sites) increased ~10-fold the number of cells transduced in the SNpc (>50% of the 5,000 to 7,000 dopaminergic neurons in the rat brain). The cholinergic neurons in the BNM were also transduced, possibly via the more caudal injection site in the striatum. This was the first demonstration of retrograde transport of a viral vector to these nuclei. For greater than 20 years the BNM have been associated with several neurodegenerative disorders, including Parkinson's and Alzheimer's disease, progressive supranuclear palsy and olivopontocerebellar atrophy [86] [87] [88] [89] . Not surprisingly, its physiological role is still poorly understood [90, 91] . Pearson et al. described neural pathologies associated with Alzheimer's disease as being consistent with the retrograde cellular degeneration in the nucleus following damage of the neocortex [92, 93] . A more recent study by Conner et al. [94, 95] suggested that the cholinergic system may be implicated in forms of learning requiring plasticity of cortical representations. Fig. (3) . In vivo gene transfer in the rat striatum with a helperdependent CAV-2 vector expressing GFP. a) GFP expression in the substantia nigra following a single injection; b) GFP expression in the basal nuclei of Meynert following a single injection in the caudal region of the striatum; c) GFP expression in the thalamus following a single injection; d) GFP expression in the substantia nigra following a triple injection (5 to 10-fold more GFP + cells as detected by confocal microscopy; e) Schematic shows the approximate sites (*) of injections in the striatum (blue), the SNpc (green), the basal nuclei of Meynert (red) and the thalamus (black).
As mentioned above, gutless Ad vectors maintain longterm transgene expression in the CNS even in the presence of a postperipheral immunization with the same Ad serotype in immunologically naïve animals. Nonetheless, the extent of the immune response generated against the capsid in the CNS of animals that have been exposed repeatedly to many different Ad serotypes, and therefore have a large and highly refined repertoire of proliferative T M [96] , is unknown. Predicting and testing the clinical safety is likely to be complex in the context of transient immunosuppression (which prevents the adaptive immune response but not the activation of a memory humoral and cellular response). The most relevant pre-clinical test may be to immunize nonhuman primates with several human Ad serotypes, stereotactically inject with a gutless CAV-2 vector into the CNS, followed with a peripheral infection with human Ads. If CAV-2 vectors continue to show encouraging results, these assays need to be addressed in the future.
In this vein, CAV-2 vectors poorly transduce and activate mature and immature human monocytes-derived dendritic cells, the professional antigen presenting cells ( [28] and M Perreau & EJ Kremer unpublished data). All but two of the 52 different human serotypes (Ad40 and 41 are the exceptions) contain a conserved Arg-Gly-Asp motif in a protruding loop in the penton. The Ad Arg-Gly-Asp motif, which is a consensus sequence that many integrin dimers use as an anchor on extracellular matrixes [97] , appears to interact with α M β 2 integrins present on dendritic cells and may lead to attachment and internalisation [83] . This motif as well as all other known integrin-interacting motifs are absent in the CAV-2 capsid [26] , yet CAV-2 internalised at essentially the same rate and efficacy as Ad5 [26] . These data suggest that either α v integrins play a minor role, or that the Arg-Gly-Asp motif is not the only integrin attachment motif in Ad internalisation.
The lack of activation of dendritic cells may be extremely pertinent when considering the potential immune response, and the possible need for repeat injections [98] . Neuronspecific transduction may also avoid side effects resulting from the ectopic expression of the therapeutic genes [99] , the MHC II presentation of the capsid proteins via infected glia, or the activation of the innate immune response via MAPK induction during infection of microglia [100] . In addition, approaches such as cell-specific restricted silencers [101] may also be incorporated to express transgenes in a subset of neurons (e.g. dopaminergic or gabanergic). Following peripheral infection with human Ads, activated macrophages/ microglia [100] and T-lymphocytes rapidly eliminate Adinfected cells in the brain [47] .
In the long-term, other possible avenues for gutless Ad vector improvement that are not linked to production (e.g. in vivo efficacy) must be explored [102] . For example the possibility of generating vectors with multiple or modified Ψ [103] , episomally replicating vectors [104] , integrating vectors that contain the AAV cassettes [105] or LINES [106] and other stuffer sequences containing GC-rich or GC-poor regions and matrix attachment sites [107] , purification based on FPLC [108] [109] [110] , etc.).
As mentioned previously, all vector platforms have disadvantages. CAV-2 agglutinates rat, monkey & human erythrocytes, which could cause adverse side effects following intracerebral injections. No clotting or occlusions have been detected to date, but must be closely monitored.
IIIc) Adeno-Associated Virus (AAV) Vectors
These nonenveloped, ~4,700 nucleotide single-stranded DNA viruses (Fig. 1b) are in the family of Parvoviridae [111] and genus "Dependovirus" -because they could only be propagated in the presence of another virus, which historically was an adenovirus [112, 113] . AAV have inverted terminal repeats (ITR) of 143 to 167 nucleotides, which are the cis-acting sequences necessary for replication and packaging. A key step in AAV biology is the synthesis of the complementary DNA strand prior to integration in the cellular genome. There are two genes, rep & cap, whose transcripts are alternatively spliced to generate the regulatory and structural proteins: rep codes for at least 4 regulatory, while cap encodes at least 3 capsid proteins. The crystal structure of AAV-2 SF3 helicase [114] , as well as the crystal structure of rep [115] , have been solved and led to a better understanding of the site-specific integration of the wild type virus in human chromosome 19 [116] . There are now 9 different AAV serotypes: (1 and 6 may be identical [117] , and 7 and 8 were isolated from rhesus monkeys), and none is known to cause clinical symptoms [7] . Of the human-derived serotypes, AAV-5 appears to be the most genetically diverse. Some surprising data even suggested that AAV infections -or more precisely the presence of anti-AAV antibodiescorrelate with lower susceptibility to certain types of cancer [118] . AAV vectors were pioneered by Nick Muzyczka and colleagues in the early 80's and now fulfil many of the requirements for gene transfer vectors [119, 120] . One of the initial drawbacks of AAV vectors was the inability to generate high titre, pure stocks. For the first ~15 years, vector preparations were often produced by transfecting plasmids containing i) the vector expression cassette (ITR-cassette-ITR), ii) rep, iii) cap, and then iv) infecting with an Ad to supply in trans the necessary proteins involved in propagation. In the last 5 years, several laboratories have successfully tweaked the system to produce and concentrate helpervirus free AAV vector preparations. In the mid 90's, the Addependent coding regions (the viral associated RNAs, E4 orf6 and the E2A genes) needed during the vector production were identified and cloned into a plasmid (the E1-encoded proteins are also needed and supplied by the producer cells) [121] [122] [123] . This strategy eliminated the need for Ad infection and concomitantly eliminated the contamination of the vector preps with Ad particles. Secondly, downregulation of the transcription [124] or translation [125] of rep increased the expression of cap: higher levels of cap in turn lead to greater vector yields. Current laboratory vector stock preparations can be produced up to 10 12 physical particles/ml. A strategy by Grimm et al. simplified the generation of vectors from six of the eight serotypes [126] : instead of the three or four plasmids previously needed, they reduced it to a cotransfection of two plasmids. The key plasmid contains i) rep from AAV-2 (which efficiently transcomplement the other serotypes, except type 5) and cap (from one of the other six serotypes); ii) the above Ad-dependent genes; and iii) a fluorescent reporter gene to follow the real time transfection efficiency. The second plasmid contains the ITR-flanked expression cassette.
An in vitro comparison of serotype transduction efficiency of brain-derived cells using human glioblastoma (A172), primary mouse astrocytes, and rat glioma cells (RG2 & C6) showed that AAV-1 was more efficient in A172, primary astrocytes and C6 cells, while AAV-2 was more efficient in RG2 cells. In vitro AAV-2, 4 and 5 vectors poorly transduced neuroprogenitor cells [127] . Due to the delay of maximum transgene expression, use of AAV vectors is not a first option for some during in vitro or in organotypic slices. However, self-complementary AAV vectors (scAAV) [128] should spontaneously re-anneal, alleviating the requirement for host-cell second strand DNA synthesis, and in turn reduce the delay in transgene expres-sion. In vitro, scAAV vectors were up to 140-fold more efficient and resulted in rapid and higher levels of transgene expression than a conventional vector. The drawback associated with scAAV vectors may be their cloning capacity (~2.4 kb).
From nearly the debut, AAV vectors were deleted in all of the viral genes and therefore did not induce a strong adaptive CD8
+ cellular immune response in naïve animals [98] . AAV vectors appear to be safe [129] , non-toxic, and preferentially infect neurons [130, 131] (Fig. 4) . They have a broad tissue and cell type tropism, transduce dividing as well as quiescent cells, and can generate long-term (>1 year) in vivo expression, especially in skeletal muscle in a number of animal models [132] . Several papers have described AAV-2 as being "neurotropic" in the CNS [130, 131, 133, 134] , while others have found that 40% of the transduced cells are a combination of micro-and macroglia [135] . For example, i) using myeloid-specific promoters Cucchiarini et al. obtained preferential expression in microglia [136] ; ii) vectors containing the myelin basic protein promoters and injected near the corpus callosum resulted in high levels of expression in oligodendrocytes [137] ; and iii) robust astrocyte-specific expression using the glial fibrillary acidic protein promoter was also found [138] . The reason for the discrepancy is probably due to the experimental design and the animal (i.e. rat versus mouse). Even within the same laboratory there is discontinuity: in 1997 Gage and colleagues [135] reported that ~66% of the AAV-2 transduced cells were neurons (rat brain) -then in 2002 [139] ** the same laboratory reported that "100% of the transduced cells were neurons" (mouse brain). It is likely that AAV-2 preferentially transduces neurons in certain regions of the mammalian brain. However, it is obvious that injection into neuron-(grey matter), or oligodendrite-rich, (white matter) regions can lead to the targeted transduction of specific cell types. The caveat is that if these vectors are variable in the rodent brain, labelling them as "neurotropic" may be misleading.
Encouragingly though, following injection of AAV-2 in the monkey caudate nucleus and putamen almost all of the infected cells displayed morphology typical of a medium spiny neuron [140] . Not surprisingly, 8 weeks postinfection no adverse histological features (e.g. perivascular cuffs or cellular infiltration) were found. Davidson et al. [134] found that using serotype 4 in the mouse lateral ventricle resulted in stable and preferential transduction of ependymal cells, with ~100-fold more transduced cells than injection with AAV-2, and 10-fold more than AAV-5 three weeks postinfection. At 15 weeks postinfection, AAV-4 and AAV-5-mediated gene transfer were essentially identical, and up to 30-fold higher than AAV-2. AAV-2 transduced cells were few, and restricted to the choroid plexus. It is conceivable that differences in the AAV-5 ITR, as well as the slower rate of second-strand synthesis, may have influenced the observed tropism.
Following striatal injections [134] , distinct regional patterns of transduction were found with serotypes 2, 4 & 5. AAV-4 transduced cells lining the ventricles in ependymaspecific expression, with very few transduced cells in the parenchyma. In contrast, AAV-2 and AAV-5 vectors transduced predominantly parenchymal cells, and unlike AAV-2 in this case, AAV-5 transduced a significant proportion of astrocytes as well as neurons. Moreover, AAV-5 transduced a greater number of cells, over a larger volume of tissue than AAV-2 and 4. The number of transduced cells using AAV-5 was 100 to 5,000-fold higher than in AAV-2. How AAV-5 was able to diffuse more readily than AA-2 & 4 is unknown and surprising (both are ~40 nm in diameter).
In vivo, a modest decrease of 2 to 5-fold was found in long-term transgene expression suggesting that re-administration of AAV vectors may be necessary in certain cases. On the other hand, and compatible with other vectors, it might be possible to inject enough vector to express 10-fold more protein than needed. One could initially downregulate the expression at the transcriptional and/or translational level, and then increase the transgene expression levels later. Following injections in the mouse cerebellar lobules, AAV-5 transduced Purkinje cells as well as stellate, basket and Golgi neurons, with occasional transduction of granule cells and deep cerebellar nuclei [141] . AAV-5 also spread outside the Fig. (4) . Example of AAV-mediated gene transfer: Recombinant AAV-2 containing a CMV-GFP expression cassette was stereotactically injected in different regions of the rat brain, 50 µm sections were labelled using polyclonal anti-GFP antibodies, and revealed using peroxidase staining and diaminobenzidinze. a) cortex; b) striatum; c) globus pallidus. (Image provided by Liliane Tenenbaum & Enni Lehtonen, Laboratory of Experimental Neurosurgery, Brussels Belgium). cerebellum to the inferior colliculus and ventricular epithelium. In contrast, in a study using the neonate mouse brain, Passini et al. found that AAV-5 showed a relatively low level of transduction [142] compared to AAV-1 and AAV-2. In the same paper, AAV-1 and AAV-2 had distinct and complementary transduction patterns, and AAV-1 significantly outperformed AAV-2. The paper describes a significantly higher number of cells in various regions transduced with AAV-1, including transduction of the ependyma and choroids plexus via the cerebral spinal fluid. It was also suggested that migrating neural progenitor cells were transduced, and in turn populated some regions. Little to no transduction of the white matter was found with AAV-1, and there was no report of axonal retrograde transport of the vectors. Lastly, Okada et al. found that AAV-5 injection in the hippocampus preferentially transduced the granular cell layer [143] , similar to the results from Di Pasquale et al. [144] .
As well as the previously mentioned cell types, AAV-2 does not appear to be specific for a subset of neurons in vitro or in vivo: cholinergic, dopaminergic, gabanergic, dentate granule neurons, etc can be transduced. As with any vector that can transduce multiple cell types, the choice of promoter can partially dictate the expression pattern. Haberman & McCowan recently reviewed some of the different choices of constitutive and regulated promoters driving transgene expression from AAV vectors in the CNS [145] . Surprising differences were seen when vectors containing different promoters were co-injected. In vivo data support earlier in vitro studies, suggesting that AAV-4 and AAV-5 enter using receptors distinct from AAV-2. The receptors for AAV-2 was reported to α v β 5 and heparan sulfate proteoglycans [146, 147] . However, there is some disagreement concerning the former [148] . Recently, the platelet-derived growth factor receptor (PDGFR) was identified as the receptor for AAV-5 [144] . It is a testament to the apparent interest in this virus as a vector that the receptor for a relatively rare AAV serotype, which causes no known disease, made such a celebrated appearance.
Recently, one laboratory found that AAV-2 vectors may be capable of trafficking via axoplasmic retrograde transport [149, 150] . After >15 years of AAV-mediated gene transfer into the CNS of thousands of animals, these results are surprising. The authors suggested that their results are due to stock preparation of higher purity, and it will be interesting to see how many laboratories can reproduce these results. If AAV-2 does traffic via axoplasmic retrograde transport, dozens of laboratories may have to rethink their published results.
Similar to the other vector platforms, AAV vectors have drawbacks. Like Ad, AAV are endemic in most populations and the presence of a T M and humoral immunity is ubiquitous. Due to the success of AAV-2 mediated gene transfer in preclinical models, the AAV field was slow in exploring other serotypes and possible nonhuman alternative [151] . Fortunately, rapid advances have been made, which is certainly due to the ease of serotype switching as mentioned above. Because most AAV serotypes are endemic, 80% of a random healthy cohort had antibodies against AAV-2 [152] . However, in the assays used only 18% had neutralising antibodies. In another population, Moskalenko et al. reported that 52% of a Sardinian cohort had AAV-2 neutralising antibodies. In another study [153] , 19 and 25% of 85 donors had AAV-1 and AAV-2 neutralising antibodies, but this humoral immunity did not cross-neutralise AAV-5. This was surprising considering the previous report using ELISA [154] showing that 60% of the population harboured anti-AAV-5 antibodies [155] .
Because of the success in animal models, little of the AAV-mediated signal transduction (which may induce cytokine and chemokine expression) has been characterised. This may be a hidden danger in the clinic. A significant innate immune response in the CNS of a patient with high memory humoral and T M immunity may trigger a more pronounced reaction than that seen in immunologically naïve animals. Many have suggested that transient immunosuppression (for ~2 weeks) may be possible in immunologically naïve patients. Sher et al. found that activated dendritic cell turnover was 7 to 10 days, which may be the window for inhibition of T cell-dependent response [156] . However, few of us are immunologically naïve to this ubiquitous virus (like human Ads). In addition, although the percentage of patients harbouring neutralising antibodies is low in some regions, opsonising antibodies and delivery to the CNS pose special risks. Rats peripherally vaccinated with wild type AAV-2 or AAV vectors showed a significantly lower level of gene transfer to the CNS [157, 158] Finally, AAV-mediated transgene expression can take from several days to weeks to appear in vivo due to the variable rate of the complementary DNA strand synthesis mentioned above [96, 159] . AAV replicates as a large concatamer, which exists either extra-chromosomally or randomly integrates [160] . AAV vector integration (at least in vitro) may also preferentially target gene-rich regions (e.g. chromosome 19q13 [161, 162] ). Sequenced AAV integration site identified a collection of plasmid DNA, mutated ITR and other anomalies demonstrating the imprecision and variability of AAV vector packaging and integration.
IIId) Herpes Simplex Virus (HSV) Vectors
HSV type 1 is a 152-kb, enveloped, linear, double stranded DNA viruses found in most populations [163] . HSV-1 is primarily associated with oral and ocular lesions and infection of most individuals occurs during childhood through a break in the mucus membrane or skin abrasions. Following this, a life-long latent infection with periodic reactivation can be established. Most recurrent infections resolve spontaneously, but rare and fatal encephalitis does occur [164] . HSV-1 initially attaches to the glycosaminoglycan moieties of cellular proteoglycans [165] before using the co-receptors in permissive cells [166] . During primary infection, the virus enters peripheral sensory nerves and migrates via axoplasmic retrograde transport along axons to sensory nerve ganglia in the CNS. During latent infection of neurons, the viral DNA exists as an episome with expression of specific genes required for latency, but physical injury, ultraviolet light, hormones, or psychological stress may abort latency (i.e. reactivate the lytic cycle). Reactivation induces the virus to traffic via axoplasmic anterograde mechanism to the surface of body and replicate (in non-nervous tissue), causing tissue damage. In vitro the lytic cycle takes less than 10 hr and invariably results in cell death [167] . Although anti-HSV-1 antibodies are common [163] , HSV-1 is capable of avoiding the immune system for decades. This latter characteristic led one to initially hope that HSV-1-derived vectors might be poorly immunogenic.
In addition to many other cell types in vitro and in vivo [168] [169] [170] , HSV-1 vectors [171, 172] efficiently infect neurons, and very efficiently traffic by retrograde transport via neurites to the soma [173, 174] . As mentioned previously, HSV-1 vectors may have been the first platform tested in the central and peripheral nervous system [174] . The axoplasmic transport of HSV-1 particles is roughly the same speed as the transport of organelles in the giant axon of Logilo pealei, (squid) [175] and of other viruses in the mammalian axons (our unpublished data). It is the virus tegument and/or the capsid proteins that are responsible for the attachment to the cellular motors, not the envelope [176] . From the inside out, HSV-1 is composed of an inner DNA core, a capsid, the tegument, and an outer lipid membrane containing glycoproteins. It is not surprising to find that the tegument is transported with the capsid; many of these proteins are needed later to initiate the virus life cycle. HSV-1 axonal migration was at a relatively consistent velocity of 2.2 µm/minute in squid axons and, unexpectedly in this study, unidirectional [176] . This supported a single transport mechanism probably based on dynein, a minus-end microtubules-based motor [177] . How HSV-1 traffics to the mucosal membrane (anterograde) to start a lytic infection is partially characterised [178, 179] . This axoplasmic transport is certainly via kinesin [175] . To further complicate HSV-1 axoplasmic transport, HSV-1 strain variation can also affect the direction of axonal trafficking in vivo [180] .
Two types of HSV-1 vectors are discussed here: replication-defective and the amplicon. Replication-competent and conditionally replication-competent are preferred in cancer therapy and are reviewed elsewhere [6, 181] . Niza Frenkel and colleagues generated the first HSV-1 amplicon vector in 1982 [182, 183] . Amplicon vectors have a theoretical cloning capacity of ~150 kb, and are plasmids containing the E. coli and HSV-1 origins of replication, HSV-1 Ψ, and a transgene expression cassette. The amplicon construct is transfected into a producer cell line and propagated using a helper virus or helper virus-free technology [184] , which provides in trans the structural and regulatory genes. Recent progress in the helper vector design has included cloning the deleted HSV-1 genome in a bacterial artificial chromosome, increasing the size of the helper genome to prevent efficient packaging, and deleting the Ψ [184] . HSV-1 amplicons may also include an Epstein-Barr virus-derived sequence needed for episomal maintenance [185] . Amplicon constructs smaller than the maximal packaging size form concatenates (in multiples that add up to ~150 kb) and therefore several copies of the transgene can be delivered per physical particle. Amplicons can be generated at titres greater than 10 8 infectious units/ml and without detectable levels of replication-competent contaminating helper vectors.
Replication-defective HSV-1 vectors can contain multiple mutations/deletions in some of the immediate early genes as well as VP16, a tegument protein that also acts as a transactivator of the immediate early promoters [172] . There are the three major obstacles to HSV-1 replication-defective vectorology: i) eliminating the replication capacity of the vector, ii) reducing the toxicity induced by many of the immediate early genes, and iii) maintaining transgene expression while the vector DNA becomes trasncriptionally inactivated [186] . There are >80 HSV-1 genes [187] , and only ~50% are needed for growth in cell culture. Once the non-essential genes have been deleted, up to 50 kb of foreign DNA can theoretically be accommodated within the vector [6] . However, this has not yet been achieved. Deletion of immediate early genes substantially reduces cytotoxicity, and also allows expression from promoters that would be silenced in the wild type latent virus.
The step-by-step evolution of HSV-1 vectors during the last 20 years has generated continually less cytotoxic vectors and has lead to increasingly longer transgene expression. In vitro HSV-1 vectors efficiently transduced the majority of neurons with a modest dose of <10 plaque forming units/cell. Similarly, in organotypic slices of mouse and rat brains HSV-1 vectors are particularly efficient in transducing neurons and lead to a robust and impressive level of transgene expression [181, 188] . In vivo, transgene expression can be detected for longer periods, but the level is orders of magnitude lower than 2 weeks postinjection. Current replication-defective HSV-1 vectors lead to significant transgene expression for up to 1 month, decline significantly, and then generate stable levels for at least 5 months [188, 189] . The bio-distribution of HSV-1 vector (5 µl at 5 x 10 9 plaque forming units/ml) following intra-hippocampus injections [190] led to expression throughout the pyramidal neurons of the hippocampal layers, predominantly in the CA3 and hilus regions but also spreading to the CA1, CA2 regions as well as the dentate gyrus. Glia showed little evidence of transduction. The diffusion of vector tended to be restricted to the hippocampus region, although occasionally there was some infection of cells in the cerebral cortex immediately surrounding the site of the needle tract [181, 188] .
A clear example of the efficient retrograde transport of HSV-1 vectors is found following footpad injections in mice and detection of transgene expression in the L3, L4, and L5 dorsal root ganglions [181] . Injection into the cerebellar cortex [191] resulted in transduction of Purkinje cells near the needle tract, while injection into the ventricles yielded no transduced neurons. High transduction efficiency was seen following injection in the inferior olive and Agudo et al. found that ~30% of the Purkinje cells over the ipsilateral and contralateral cerebellar hemispheres were transduced (probably via retrograde axonal transport from the cerebellar nuclei) [191] . Like CAV-2 vectors, injection of HSV-1 vectors into the striatum leads to high levels of retrograde transport and significant expression in afferent structures like the SNpc and the neocortex [188] .
Because of the natural tendency to inactivate the transcription of the HSV-1 genome the theoretical ability to include multiple expression cassettes has also not been achieved in replication-defective vectors. However, Jacobs et al. expressed three genes (GFP, thymidine kinase, and cytosine deaminase) simultaneously in an amplicon vector [192] . In replication-defective vectors the expression cassette must be placed near one of the two the latency activating promoters (LAP1 and LAP2). LAP1 is believed to responsible for expression during the latent phase, while LAP2 is responsible for the lytic phase. The latency-activated transcripts may enhance the establishment of latent infection by preventing apoptosis in neurons [193, 194] . Like many complex viruses, vector production is often inversely related to the number of genes deleted and supplied in trans. Ozuer et al. assayed several HSV-1 vector production parameters and optimised production before concentration [195] .
The enormous potential of HSV-1 vectors has been slow to be completely exploited because of the induced immunogenicity and cytotoxicity of the vectors. The immediate early gene products (ICPO, ICP4, ICP22, ICP27, and ICP47) appear to the most cytotoxic. In an interesting twist, ICPO may be "tolerated" in vectors destined for the CNS: the ICPO mRNA appears to be degraded preferentially and rapidly in neurons [196] . Although cellular and humoral immunity (adaptive) is critical in the resolution of viral infections, the innate immune response also plays a significant role. HSV-1 (and Ad) vectors have been shown to induce phagocyte activation including macrophages and neutrophils within the first 48 hr postinjection [197] . Activated phagocytes release the pro-inflammatory cytokines interleukin-1β (IL-1β), tumour necrosis factor-α, (TNF-α) and interferon-γ, (IFN-γ) which initiate the acute phase response, followed by chemokine and adhesion molecule (ICAM-1) expression that increases trafficking of additional phagocytes to the injection site. As mentioned above, collectively these aspects of the innate response enhance adaptive immunity. Wood et al. observed strong inflammatory responses to HSV-1 amplicon vectors, both at the primary and secondary (supplied by nerve fibres) site of the injection [198] . In vitro in epithelial cells, HSV-1 triggers activation of Ca +2 -signalling pathway during internalisations [199] and Ca +2 influx may be tightly linked to downstream signal transduction, including focal adhesion kinase (FAK) and other kinases, needed to induce actin reorganisation and virus internalisation.
The improvement in HSV-1 amplicon vector purity has decreased the innate immune response following vector injection in the mouse CNS. Olschowka et al. found that HSV-1 amplicons free of helper vector contamination induced a significant innate immune response 1 day postinjection in the mouse CNS, which was similar to amplicons containing contaminating helper vectors [197, 200] . However, 5 days postinjection levels of ICAM-1, IL-1β, MCP and IP-10 decreased significantly (versus helper vector contaminated stocks) and eventually returned to near baseline levels (PBS injected controls).
IIIe) Simian Virus-40 (SV40) Vectors
SV40 is a nonenveloped, circular, integrating, doublestranded DNA virus of 5.25 kb from the Papovavirus family [201] . It has a diameter of ~45 nm (Fig. 1d) , and with 11 other viruses (including JC virus and BK virus) belongs to the subfamily Polyomavirinae. Because of the ease in handling, its small genome, and its ability to transform cells, SV40 is rather well characterised. It was one of the first organisms entirely sequenced [202, 203] , and its restriction enzyme pattern was studied in the early 70's. SV40 completes a productive lytic infectious cycle in monkeys, but not in humans. Deletion of the Tag gene, which is expressed before replication cycle begins, makes the vector replicationdefective in cells that do not express the large T antigen.
Replication-defective SV40 vectors were originally used in vitro in 1981 by Gething and Sambrook [204] and the first in vivo use was reported in 1996 by DS Strayer [205] . Similar to gutless Ad, HSV-1 amplicons, and AAV vectors these SV40 vectors contain only the cis-acting sequences needed for replication (ori) and Ψ and do not contain viral coding sequences. The protocol for generating replicationdefective SV40 vectors is straightforward: the vector genome is excised from the plasmid backbone, circularised, transfected in large T antigen transcomplementing cells and then serially amplified. More recently, Michael Gottesman and colleagues generated an in vitro packaging system using either four of the SV40 proteins (VP1, VP2, VP3 and agno) or just one (VP1). This approach increased the cloning capacity up to 17 kbp [206, 207] although large cassettes (>9.5 kb) were more efficiently packaged by VP1 only. It is likely that VP-only capsid is less rigid and can accommodate larger DNA fragments. The current drawback with in vitro packaged SV40 vectors may be the modest titres (up to 5 x 10 5 particles/ml) and inability to upscale the reaction.
Surprisingly, replication-defective SV40 vectors are not widely used although they harbour many of the intrinsic characteristics needed for gene transfer in the CNS. They i) can be concentrated to >10 12 infectious particles/ml; ii) do not induce a humoral or cellular immune response; iii) have a cloning capacity of ~5 kb; iv) transduce dividing and quiescent cells; and v) leads to long-term stable expression in vivo. In an odd twist, some SV40 vectors poorly express some prokaryotic or invertebrate transgenes (e.g. lacZ & GFP), which has probably complicated the in vivo biodistribution studies of the vectors, and may be preventing its widespread study and use. To date, no retrograde transport has been reported (personal communication DS Strayer) . SV40 vectors also infect almost all mammalian cell types using the MHC-I complex [208] .
The extremely novel characteristic of SV40 vectors is the apparent lack of induced immune response, which allows multiple repeated injections [209, 210] . Even the protein load from the injection of the vector capsid proteins apparently does not induce a humoral response -unlike the wild type virus. The SV40 capsid is not processed by the fusion of endosome or phagosomes with the lysosome. Following attachment to the MHC-I complex SV40 enters via caveolae in lipid rafts [211, 212] **, which is associated with an ERK/MAPK-independent signalling cascade [213] , and is delivered to the endoplasmic reticulum transport system to be deposited at the nuclear pore.
In vitro SV40 vectors lead to long-term transgene expression in human NT2-derived neurons without reported toxicity. Although long-term transgene expression in the CNS has not been demonstrated, preliminary data suggests that it should be possible with most expression cassettes (Fig. 5) . Following intraventricularly or interstriatal injection in the rat brain Cordelier et al. reported that SV40 vectors transduced neurons, microglia, and perivascular cells, which were most likely macrophages [214] . It is not surprising that microglia, the immune mediator cells of the CNS, which express high levels of MHC-I complex [48] , were efficiently transduced. No data describing the number of cells, or the area transduced were given. SV40-mediated transgene expression in astrocytes appears to be very inefficient (DS Strayer personal communication).
In a more unusual observation that does not appear to have been examined more closely, neurons and astrocytes were positive for transgene expression following intravenous injection in adult BALB/CJ mice [215] . These data suggest that either SV40 is able to cross the blood brain barrier and/or that other cells were transduced and migrated into the CNS. Regardless of the mechanism, these data are potentially very interesting and need to be more closely examined.
IV) RNA VIRUS VECTORS
IVa) Alphavirus Vectors
Alphaviruses (Fig. 1e) are some of the most simple enveloped animal viruses, have a positive-strand ~12,000 nucleotide genome, and are members of the Togavirus family [216] . They are found throughout the world, are transmitted by mosquitoes, and naturally propagate in small mammals and birds using the MHC I molecule, laminin and other receptors to infect cells. Alphaviruses replicate in the cytoplasm, and therefore do not integrate into the host genome. The viruses and vectors replicate using their own RNA replicase. Wild type alphaviruses inhibit host cell protein synthesis, are cytotoxic and cause fatal disease in newborn and suckling rodents. Following the occasional infection of humans most cases lead to subclinical conditions, but sporadically alphavirus infections can lead to encephalitis. A general feature of alphaviruses is that small point mutations can dramatically change the course of the disease in the host.
Current alphavirus vectors (for review see [217] ) are derived from Venezuelan equine encephalitis virus, Sindbis virus (the prototype alphavirus) and Semliki forest virus (SFV). To generate vectors, the ~12,000 nucleotide viruses are deleted in the genes coding for the structural proteins and mutated in the genes coding for the non-structural proteins 1-4 (nsP1-nsP4) regions, generating a cloning capacity of up to 6 kb. An advantage of alphavirus vectors is their rapid production and reasonable titres (10 8 infectious particles/ml). One method to produce recombinant Sindbis vectors is to cotransfect viral mRNA coding for structural proteins with the RNA transcript of the vector. Several laboratories have used these vectors to produce impressive quantities of recombinant proteins [217, 218] .
Using early generation of alphavirus vectors, many laboratories found a rapid (6 hr postinfection) and robust level of transgene expression in vitro and ex vivo in organotypic slice cultures (Fig. 6) [217, 219] . However, an initial drawback with alphavirus vectors was the rapid shutoff of host protein synthesis, which concurrently led to cytotoxicity and transient transgene expression (~3 days). Recent attenuated alphavirus vectors contain point mutations in nsP2 and nsP4, which render the virus defective or temperature- Fig. (5) . Example of SV40-mediated gene transfer in the rat caudate-putamen: 10 8 infectious units of SV(nef-FLAG), which expresses an HIV Nef coding sequences, with a C-terminal FLAG epitope was injected on day 1. Seven days postinjection, the caudate-putamen was formalin-fixed and -sectioned after fixation and stained for a) NeuN (neuron marker b) FLAG (using a polyclonal anti-FLAG antibody). sensitive. Combining some of these mutations led to a synergistic effect and in turn decreased host protein shutoff, and increased the duration of transgene expression. In organotypic slice cultures, a temperature-sensitive (31°C) triple-mutated SFV vector generated stable transgene expression for >20 days postinfection [220] . In organotypic cultures of rat hippocampus, Sindbis vectors efficiently transduced CA1 neurons [221] and 36 hr postinfection the electrophysiological parameters of infected neurons were not significantly different from non-infected neurons. In primary hippocampal cultures Kim et al. found that >80% of the transduced cells were neurons. The same laboratory also stereotaxically injected GFP-expressing Sindbis vectors (containing mutations in the nsP2 regions) into the layer 2/3 somatosensory neocortex of 3-week old rats. After 24-36 hr transgene expression resulted in strong but transient labelling of a small population of cortical pyramidal cells [222] .
Using a GFP-expressing vector derived from an avirulent SFV strain {A7(74)} Ehrengruber et al. found that in hippocampal tissue at 37°C, glia almost exclusively expressed the transgene [223] . At 31°C, however, a more wild-type phenotype was found, with 33% and 94% of the GFP + cells being neurons in slices and dissociated cells, respectively. Using a second SFV variant (VA7) 94% of the transduced cells were neurons in hippocampal slices. These results show that in addition to the developmental age, the temperature determines which cell type becomes "infected" (or maybe more precisely -express virally encoded genes) and in turn determines the clinical "tropism" of SFV. The receptor used by alphaviruses to infect neurons does not appear to be laminin, but instead a 74 or 10 kDa protein [224] . Finally, Sato et al. compared the tropism and efficacy of SFV to a ∆E1 Ad vector in dissociated and slice cultures of the mouse cerebellum [225] . In dissociated cultures 90% of the Purkinje cells and 40% of CGC were positive with the SFV vector (~0.03 to 2 infectious particles/cell), while the control Ad vector (30 plaque forming units/cell) infected essentially all the cells in the culture. In slice cultures, each vector preferentially infected glia in the white matter and as well as a few CGC in the internal granular layer and Purkinje cells.
As mentioned above, long-term in vivo gene transfer is currently limited because of the cytopathic effect of the vectors at 37°C. For the moment, this precludes the detailed analysis of the innate and induced immune response induced by these vectors. However, Gwag et al. reported that no OX-42 immunoreactivity (macrophage/microglia activation) was detected following in vivo gene transfer [226] . It is likely that alphavirus vectors will induce NF-κB and INF-γ in vivo via the interaction with the Toll-like receptors 3 and 4 [227, 228] , which upregulate cytotoxic protein kinase-RNA and 2', 5' oligoadenylate. No retrograde transport of alphavirus vectors has been reported. Due to the current limited duration of transgene expression and relatively cytotoxic, SV40 vector may be useful during short-term studies in organotypic slices and clinically relevant in the context of cancer therapy to the CNS.
IVb) Lentivirus Vectors
Lentivirus (Fig. 1f) are enveloped retroviruses with a diploid genome of ~8 kb belonging to the family Retroviridae, and are found in a wide range of species [229] . The best way to understand the biology of these complex viruses is to assume an antithesis of classical viral diseases. Lentivirus (lenti = slow Latin) take months to years to induce clinical symptoms that persist indefinitely, have high mutation rates, and often lead to wasting and death of the host. The high mutation rate induces the various changes in intra-host tropism and infection of other tissues. Human immunodeficiency virus type 1 (HIV-1) was partially characterised in the early 80's, sheep lentivirus (VMV) was described in the 50's by Sigurdsson [230] , while equine infectious anaemia virus (EIAV) has been known for at least a century. In vivo lentivirus spread almost exclusively via cell-cell contact, and the life cycle is ~20 hr in vitro.
There are three principle regions of the virus genome: Gag (which encodes the matrix, capsid and nucleocapsid proteins), Pol, and Env (envelope). A fourth region, whose genes are dispersed throughout the genome, encodes accessory proteins (vif, vpr, vpu, and nef) is not essential for vector production in vitro. A reverse transcriptase steps (which starts before internalisation and finishes in the cytoplasm) creates the proviral double-stranded DNA. The nuclear import of the double-stranded DNA in nondividing cells, via a proteanacious pre-integration complex that carries karyophylic determinants, is one of the key determinants that separate lentiviruses from most of the oncoretroviruses (e.g. Moloney murine leukaemia virus). The HIV-1 proviral genome preferentially integrates at transcriptionally active sites [231] downstream of the transcriptional start site [232] . Most cells infected by HIV persist only for a few days before they are eliminated, either by the cytopathic effect or by the immune system. Thus, the HIV provirus maximizes its production by producing the largest number possible in the short time available, and high-level transcription in transcriptionally active regions may aid propagation. Virus particles assemble and bud at the cell surface via the interaction of the unspilced viral RNA with gag and pol on the cytoplasmic surface. The complex buds into vesicles containing env on extracellular surface.
In the CNS, productive HIV-1 infection may be confined to monocyte lineage cells in the choroid plexus, where the incidence of infection is actually higher than in brain and is present prior to the onset of AIDS. The presence of perineuronal CD4 + T cells, as well as activated microglia, suggest a trans-receptor mechanism of viral entry whereas intrinsic gene profiles do not appear to participate in conferring selective neuronal vulnerability or resistance to infection [233] . Restricted or latent HIV-1 infection may also occur in astrocytes and neurons, which may serve as an in vivo reservoir. However, this view is not universally shared because HIV-1 poorly infects neurons. The receptors for the HIV-1 glycoprotein env is CD4 [234, 235] and the coreceptors are CCR5 and CXCR4 [236] , Luigi Naldini and Didier Trono pioneered HIV-derived vectors in 1996 [237] . The potential risks associated with vectors derived from HIV-1 and 2, which cause AIDS, hindered its initial development, use and acceptance as a potential clinically relevant tool. HIV vectors have a cloning capacity of ~8 kb and can be generated following a triple transfection in 293T cells. To prevent the generation of replication-competent viruses via homologous recombination, the plasmids used in the triple-transfection i) do not containing overlapping regions of the viral genome; ii) have been codon optimised; iii) have replaced viral promoters and poly-adenylation signals by more efficient ones; iv) have modified or deleted cis-acting package sequences (for review see [238] ); v) have split Gag-Pol sequences; and vi) have used cross-packaging constructs (e.g. using gag from one and pol from a second) [239] .
During production, lentivirus vectors can readily be pseudotyped (incorporation of heterologous Env proteins in the virus particle) with surface glycoproteins from other retroviruses or non-retroviral glycoproteins (e.g. Rhabdoviridae family vesiculoviruses & lyssaviruses (rabies) [240, 241] ; hepadnaviruses (hepatitis B) [242] , flaviviridae (hepatitis c) [243] , Filoviridae (Ebola & Marburg), arenavirus (lymphocytic choriomenigitis virus, LCMV) and others (for review see [244] ). There are two models for the particle formation. A passive model includes Env incorporation via non-obligatory interaction between the viral core and the pseudotyping glycoprotein. In this scenario the glycoprotein must be sufficiently abundant and not contain a cytoplasmic tales that prevents efficient virion assembly. The second model is an active model where the interaction of the Env cytoplasmic tail favours or attracts the virion core. Lentivirus pseudotyping significantly modifies the tropism and their in vivo characteristics, and for this reason, it is difficult and often confusing to speak generally about lentivirus vector tropism.
VSVG, the vesicular stomatitis virus glycoprotein, is the most widely used glycoprotein because it stabilizes the particles, allows one to readily concentrate particle, and induces a wide tropism. In rodents VSVG pseudotyped lentivirus vectors are very efficient in CNS tissue (Fig. 7) [135, 237, 245] , and lead to a preferential (>80%) infection of neurons in the mouse brain. Unfortunately, VSVG is rapidly inactivated by human serum [246] , which will probably limit its use in the clinic. In neurons VSVG is thought to interact with membrane phospatidylserine [247] .
Like some of the previous described vectors, lentivirus vectors are not derived exclusively from the two known human serotypes (HIV-1 and HIV-2) [248] . Bovine (BIV) [249] , feline (FIV) [250, 251] , equine infectious anaemia (EIAV) [252] , and simian (SIV) [253] viruses have also been converted into vectors. These nonhuman-derived lentivirus vectors may skirt some of the reservations about the use of HIV-derived vectors. Furthermore, pseudotyping of these creates a broad range of potential vector systems with subtle differences. For the sake of simplicity (see the caveats below), one can consider that if the specific pseudotyped lentivirus vector can be produced, its tropism and axonal retrograde transport will be roughly similar. Mazarakis et al.
[254]** recently assayed EIAV vectors pseudotyped with VSVG (Indiana or Chandipura strains), two rabies strains, Mokola and LCMV for their efficacy in the rat striatum. I) A VSVG pseudotyped Indiana strain vector efficiently (~2 x 10 4 cells) and preferentially (~95%) transduced neurons at the site of injection. No retrograde transport was detected [255] . Following injection of rabies CVS strain pseudotyped EIAV vectors in the striatum, intraspinal and newborn mouse gastrocnemius, transgene expression was detected in the contralateral side of the spinal cord, the brain stem, the neocortex, or to the motor neurons in the spinal cord, respectively. A caveat though: in these intramuscular injections, the volume injected (30 µl or ~3 x 10 9 infectious particles) was almost equivalent to the volume of the muscle.
The above data also suggest that the molecular motors involved in retrograde transport of the pseudotyped vectors are using part of the envelope, and/or the site of internalisation (based on the location of the envelope's membrane receptor) is (are) significantly different. During classical in vitro vector mode of entry, the envelope is lost via the fusion with the cell membrane (this is probably much different to the in vivo virus propagation via transcytosis). This would leave the capsid free in the cytoplasm to attach to the motors, or it could undergo further disassembly and the preintegration complex could be transported. On the other hand, the vector could be internalised via receptor-mediated endocytosis and transported in vesicles. This is the scenario with poliovirus: the cytoplasmic tail of CD155 (the poliovirus receptor) associates strongly with a light chain of the dynein motor complex, a major driving force in retrograde transport [256] . Rabies virus is usually transmitted through a break in the skin and spreading by retrograde transport, and replicating in neurons. Rabies-G interacts with neural cell adhesion molecule, p75, a low affinity neurotrophin receptor (NTR), and the acetylcholine receptor [257] [258] [259] . Spreading is thought to be via a transynaptic route before and after replication, and dependent upon rabies-G protein [260] . It is therefore probable that pseudotyped vectors are transported in vesicles containing the specific env receptors. In addition to the fascinating fundamental aspects of the tropism and retrograde transport, the successful pseudotyping of lentivirus vectors with other envelopes expands the possibility of these vectors in the CNS. Also a degree of transcriptional immunity seems to protect lentivirus vectors from their genomic environment (i.e. there does not appear to be the same degree of promoter inactivation in vivo as seen with oncoretroviruses [261] ).
Are there other problems with lentivirus vectors? Many laboratories have detected an acute inflammation and cellular infiltration following injection with lentivirus vectors. To remove the contaminating cellular and viral proteins from the vector preparations Baekelandt et al. added a purification step on a sucrose gradient. This added step reduced the induced immune response from less purified preparationsbut also significantly reduced the titre [262] .
Secondly, serotypes-specific lentivirus restriction has emerged as a dynamic subject relevant to pathogenesis research and lentivirus vector-based gene therapy. The restriction of retrovirus infection is postentry and normally before the reverse transcribed DNA is integrated into the host genome. The murine gene Fv1, which encodes a Gaglike protein, is able to block Moloney murine leukaemia virus infection [263] . The block is saturable, occurs after reverse transcription and is directed against the viral capsid. Several other mammalian species are also able to block Moloney murine leukaemia virus infection with the same capsid specificity (e.g. human Ref1 gene). Recently, primates have been shown to restrict a variety of retroviruses only very distantly related to Moloney murine leukaemia virus through Lv1. Restricted lentiviruses include HIV-1 and 2, SIV and EIAV {for review see [264] }. For example, HIV-1 is restricted in cells from rabbits, owl monkeys, rhesus macaque, and African green monkeys. EIAV is restricted in African green monkeys cells and is 10-fold less efficiency in human cells versus HIV-1 when normalised to viral particles. EIAV is ~3-fold more efficient in murine cells than in human cells [265] . In each case the block can be saturated by co-infection with a second restricted virus. The mechanisms of action and evolutionary consequences of restriction are currently being unravelled [264] . Recently a human gene (APOBEC3G) was identified that restricts lentivirus infection [266] [267] [268] [269] [270] [271] **. APOBEC3G is a cytosine deaminase incorporated into HIV-1 virions that mutates viral DNA as it is synthesized. The HIV-1 protein Vif acts to neutralise APOBEC3G and allow infection-however Vif appears to be species-specific and does not act on nonhuman homologues.
More simply put, nonhuman lentivirus vector efficacy in rodents and other laboratory animals may not correlate with their clinical potential. There are potential solutions to these current drawbacks (e.g. include a Vif homologue in nonhuman lentivirus vectors to inactivate APOBEC3G), but the eventual safety of these recombinant hybrid vectors is unknown.
V) TRANSDUCTION VERSUS SURVIVAL OF NEURONS
While there are several strategies to transduce neurons, it is another issue to keep their biological function intact following genetic modification. Many of the preclinical in vivo gene transfer studies examining the efficacy of vectormediated gene transfer have been in healthy brains. How fragile and sensitized neurons in a damaged CNS react to viral vectors will obviously vary between animal models, patients and disorders. The most studied CNS models have been in mouse and rat, however several others including the dog, cat, guinea pig and nonhuman primate have also been examined. A caveat for clinical gene transfer though is that the human putamen is ~10-fold larger than that of the rhesus monkeys, and the rat brain is often smaller than the end of a man's thumb. In clinical gene transfer, the risk-benefit ratios depends on three basic criteria: i) risk of an adverse event to the patient in the immediate or distant future; ii) risk to the public by spreading the therapeutic agent; and iii) the possibility of genetic contamination of the germ line. The latter two are sine qua non for patient safety, which is complex especially in Phase I trials. Notably, it is possible to kill a patient more quickly by encephalitis, sepsis, haemorrhage or an aneurism than by most neurodegenerative disorders.
Though most clinical gene transfer attention has focused on cancer therapy, there have been notable successes in several animal models. Several reviews have focused on gene transfer for Parkinson's [272] , Huntington's [2] , amyotrophic lateral sclerosis [149, 150] , multiple sclerosis [273, 274] , and lysosomal storage disease [275, 276] . AAV vectors have been tested to counteract neuronal degeneration using glial-derived neurotropic factor or bcl-2 in parkinsonian rats [130] or using brain-derived neurotropic factor or insulin-like growth factor in a mouse model for amyotrophic lateral sclerosis [150, 277] . In addition, rubrospinal neurons in the magnocellular part of the red nucleus can be rescued from lesion-induced atrophy with an AAV-2 vector encoding brain-derived neurotropic factor [278] . Parkinson's disease has been targeted by expressing tyrosine hydroxylase in striatal cells [279, 280] , thus replacing the supply of L-dopa. Federoff et al. [281] induced nerve repair following axotomy of the superior cervical ganglion, by injection of an HSV-1 vector expression nerve growth factor. In certain experimental designs, short-term, non-toxic, non-inflammatory transgene expression may be preferable.
Mixtures of three AAV-2 vectors expressing dopamine synthesizing enzymes (tyrosine hydroxylase, l-aromatic amino acid decarboxylase and GTP cyclohydrolase-1) injected unilaterally into the putamen of Parkinsonian monkeys demonstrate both the limited cloning capacity, and the power of AAV vectors [282] . Gene transfer resulted in marked improvement in manual dexterity on the contralateral side with robust transgene expression and elevated dopamine synthesis. Monkeys picked up raisins better with the contralateral hand, while the ipsilateral limb remained disabled, and behavioural recovery persisted for >18 months postinjection. After AAV vector injections, animals demonstrated apomorphine-induced dystonic postures, in which the body and face turned toward the ipsilateral side, and a circling tendency toward the ipsilateral side, indicating reduced dopaminergic receptor supersensitivity in the injected putamen. Tyrosine hydroxylase, l-aromatic amino acid decarboxylase and GTP cyclohydrolase-1 immunoreactive cells were present in >90% of the putamen. An infiltration of mononuclear cells was found (it was not discussed if the monkeys had anti-AAV antibodies) and residual hemosiderin around the needle tract, hematoxylin and eosin staining revealed no signs of cytotoxicity in the AAV vector-injected putamen. Monkeys did not show complications (e.g. dyskinesia) related to AAV vector injection.
We are concentrating on the neurodegenerative damage caused by rare orphan lysosomal storage disorders (LSDs). There are a number of unique characteristics of several LSDs that make gene therapy potentially plausible. LSDs are generally well-characterized monogenetic disorders and naturally occurring and KO mouse and large animal models exist, which should allow testing of the therapeutic efficacy. The amount of enzyme required for cellular correction varies with each disease (~40 different LSDs), but may be 1-10% of normal levels, based on the observed enzyme levels in individuals with milder, late-onset disease. For example, some patients with ~10% of the normal level of β-glucuronidase activity/cell have no clinical symptoms [283] . Enzyme replacement therapy [284] is feasible because extracellular enzyme can be recaptured by the mannose 6-PO 4 receptor, which is present, albeit in different amounts, on essentially all cells. A proportion of many newly synthesized lysosomal enzymes escape from the cell and into the extracellular space and into the systemic or lymphatic circulation. This includes overproduced extracellular enzyme from genetically modified cells, and therefore other enzyme-deficient cells (e.g. oligodendrocytes, micro-& macroglia & neurons) in contact with genetically modified cells are "treated". Notably, William Sly and colleagues found that high-level expression of β-glucuronidase in transgenic mice did not adversely affect the cells [285] *. Some lysosomal enzymes also travel via retrograde and anterograde transport in neurons [286] . AAV vectors have been tested in mucopolysaccharidosis VII models [287] . A surprising result was the distribution of β-glucuronidase activity when AAV-1 or AAV-2 vectors were tested [142] : a disproportionate increase in enzyme distribution was found when AAV-1 vectors were delivered. Intracranial injections of recombinant FIV vectors encoding β-glucuronidase into MPS VII mice resulted not only in the correction of the characteristic cellular pathologies, but also in improvements in cognitive function [288] *. A similar demonstration of protection from disease-associated pathology was also reported for metachromatic leukodystrophy using a lentivirus vector expressing arylsulfatase A [289] . Although expression of the enzymes was concentrated at the sites of injection, the pathology resulting from storage was reduced in most areas of the brain. While these results are extremely encouraging, more studies are needed to assay the potential efficacy in larger brains. In addition, although a few of the studies were performed in adult mice with developed CNS pathology rather than very young animals, it will be important to determine the window for effective therapy.
SUMMARY
Although it has been written many times, it cannot be repeated too often -all vectors will have advantages and disadvantages. Moreover, no single vector will be appropriate for all assays, approaches, or therapies. The criteria for an appropriate vector mentioned in this review are also (unintentionally) biased, limited due to space constraints, and directed toward the current mainstream use of gene transfer approaches (e.g. the genetic modification of oligodendrocytes, especially in the case of metachromatic leukodystrophy, was not addressed). There has been, and will continue to be, exciting advances and improvements in hybrid vectors, synthetic vectors, electroporation of naked DNA, and titres and purity of the present vectors. Genetic and non-genetic approaches (e.g. coating capsid proteins with polymers and then covalently linking growth factors or peptides) are also being used to modify vector tropism and utility. Regulatable transcription or translational control, tissue and cell type specific promoters, use of internal ribosome entry sites that are species and tissue specific, are just some of the options that must be combined to address many issues. One of the many challenges for functional genomic studies is to combine these tools with microarray analysis to determine how the modification (i.e. knock-in or knock-out) of a locus affects neurodegenerative diseases, and complex abnormal behaviour patterns like schizophrenia, drug abuse, and alcoholism. As mentioned previously, the brain is the most complicated organ with more genes expressed than any other tissue. Even the best microarrays do not reproducibly and reliably detect all brain-specific genes [290] . This lack of sensitivity is certainly due to the specific physiological roles and therefore expression of a subset of genes in isolated, distinct and small nuclei within the CNS.
If one takes a well known complex neurodegenerative disorder like Parkinson's disease and tries to use gene transfer to understand the role of oxidative stress, neurotrophic factors or enzymes (e.g. those that synthesize dopamine), one can quickly appreciate the need to use various vectors to target different populations of cells. If one wanted to express tyrosine hydroxylase, l-aromatic amino acid decarboxylase and GTP cyclohydrolase-1 from the same vector and specifically in the neurons of the SNpc that project into the caudate putamen, what would be the appropriate vector? If one wanted to overexpress glial-derived neurotrophic factor exclusively in astrocytes of the caudate putamen -which vector would one choose? How would one assay the specific role of the cholinergic neurons in the basal nuclei of Meynert in Parkinson's disease? How could one use in vivo inducible transcriptional regulation, in combination with RNAi technology, to address the role of pesticides? Using microarrays could one predict, understand and eventually circumvent behavioural modification due to aberrant expression of neurotrophic factors in distinct regions of the CNS? How can we use vectors and genomic assays to understand dominant negative mutations in neurodegenerative disorders? More related to the field of infectious disease and gene transfer, how could one use a genomic approach to understand the innate immune response in vivo and the induced signalling cascade during vector-cell contact, vector internalisation or integration of the vector sequences into cellular genome?
With ingenuity, honesty, and rapid sharing of reagents and findings, we can move forward with considerable optimism.
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